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 ‘>Žǁ'ƌĂĚĞ'ůŝŽŵĂ ? ?ŶhƉĚĂƚĞĨŽƌZĂĚŝŽůŽŐŝƐƚƐ 
 
Abstract 
With the recent publication of a new World Health Organization (WHO) brain tumour 
classification that reflects increased understanding of glioma tumour genetics there is a 
need for radiologists to understand the changes and their implications for patient 
management. There has also been an increasing trend for adopting earlier, more 
aggressive surgical approaches to ?low grade glioma? treatment. We will summarise these 
changes, give some context to the increased role of tumour genetics and discuss the 
associated implications for radiologists of their adoption. We will discuss the earlier and 
more radical surgical resection of low grade gliomas and what it means for imaging 
patients. 
 
Background 
Diffuse  ‘low grade gliomas (LGG) ? are tumours of glial tissue which are generally slow-
growing, but have the potential to undergo anaplastic progression into more aggressive 
tumours. For the best part of the past century glial tumours have been grouped based on 
histological appearance 1,2, and this approach formed the basis of the 2007 World Health 
Organization (WHO) Classification of Tumours of the Central Nervous System.3 This system 
graded diffuse gliomas based on morphological features, reflecting biological behaviour, 
into grades II-IV with grade II being low-grade and grades III and IV being high-grade.3 WHO 
grade II are astrocytomas, oligodendrogliomas, and oligastrocytomas (although see below).4 
The recently published updated WHO classification, however, now contains some significant 
changes in the approach to the classification of LGG (and the higher grade gliomas). In 
particularly, molecular findings are now integral to a full diagnostic categorisation of these 
tumours. 
 
It is important at this point to say something about terminology. dŚĞƚĞƌŵ ‘ůŽǁŐƌĂĚĞŐůŝŽŵĂ 
(LGG) ?is commonly used in the literature to refer to grade II gliomas as a group in both 
clinical and radiological literature. Whilst this is a useful grouping it should be noted that 
LGG is not used in the WHO classification and is not a final neuropathological diagnosis. 
Furthermore, it should be appreciated that grade II gliomas are not benign tumours, given 
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their infiltrative behaviour and eventual progression to more aggressive grade III and IV 
tumours with an associated poor prognosis. Thus they have a /3 malignancy grading in the 
International Classification for Diseases of Oncology (ICD-0). Grade I tumours, such as 
pilocytic astrocytoma, are also often included in the term LGG. As these are benign and 
considered a separate entity, they are not included within the scope of this article, which is 
therefore restricted to the WHO grade II gliomas. LGG is used within this review to refer to 
WHO grade II gliomas, as this is the terminology currently used in clinical practice and 
widely understood by clinicians and radiologists alike, but it is important to note these 
caveats, and that it should not be considered as a final diagnostic label. 
 
Despite LGG being sometimes indolent in behaviour, it is estimated that approximately 70% 
will undergo anaplastic progression into high-grade tumours within 5-10 years of diagnosis.5 
This progression is unpredictable and varied and consequently the management of LGG has 
been debated for some time. Expectant management has been the norm in many centres 
for stable LGG showing no signs of further anaplastic progression, particularly as LGG tend 
to occur in eloquent brain areas. This has arisen out of the supposition that intervention and 
treatment can cause greater adverse effects than benefits in these patients, as well as the 
conflict of opinions on the benefit of early surgical resection, radiotherapy or chemotherapy 
in improving overall and progression-free survival. Many institutions have therefore 
adopted an imaging-based monitoring policy for LGG, with intervention being initiated when 
changes suggestive of anaplastic progression occur. Radiologists have played a key role, 
monitoring and identifying signs suggestive of anaplastic progression, traditionally by an 
increase in tumour diameter and new areas of contrast enhancement. Research has 
therefore also been focused in this area, aiming to identify non-invasive surveillance 
methods to allow early, yet sensitive and specific, detection of anaplastic progression. A 
variety of magnetic resonance imaging (MRI) based techniques have been explored for this 
purpose, including diffusion-weighted imaging6 W14, perfusion weighted imaging6,8,10,15 W21 and 
magnetic resonance spectroscopy10,12,16,22 W27. However, despite the plethora of research into 
imaging biomarkers of anaplastic progression, the results have been varied with no 
definitive predictive marker being found that has been universally accepted. 
 
Some grade II gliomas rapidly progress within a very short time period, whereas others 
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remain stable for many years. It has therefore become readily apparent that the 2007 WHO 
histological typing and grading system does not always allow accurate prediction of tumour 
behaviour, response to treatment and patient prognosis, despite being based on 
morphological features reflective of biological behaviours. There are several reasons why 
this may be the case. LGG are heterogeneous in nature both within a single tumour resulting 
in potential sampling errors at biopsy and also amongst each other reflecting genetic 
diversity within this group of tumours. There is also suboptimal intra- and inter-observer 
reliability between pathologists28,29. This limits the usefulness of biopsy specimens which, 
combined with the apparent failure of MR imaging to provide a widely accepted and reliable 
biomarker of future tumour behaviour and progression risk, has led to recent research into 
the genetic make-up of LGG. The conflicting evidence reported for the various MR 
biomarkers previously studied as markers of progression is almost certainly attributable to 
the diverse nature of gliomas and differences in molecular status of tumours within the 
same histological grading.  
 
There have been significant advances in the understanding of molecular genetic 
abnormalities in the pathogenesis of brain tumours. The new update to the WHO 
Classification of Tumours of the Central Nervous System, published this year, incorporates 
molecular abnormalities into the neuropathological assessment of gliomas, and as such is a 
departure from the primarily morphological approach used in the previous classification.30 
Key changes in the new classification have been recently reviewed.2 This update has thus 
radically restructured the classification of gliomas, which is now based on integrated 
molecular and histological parameters.2 This review article aims to summarise the recent 
key findings in LGG genetics research and how these findings have shaped the latest 2016 
WHO classification,2 as well as the shift towards more aggressive surgical management. It 
will focus on the changing role of imaging and the impact of this on the radiologist in the 
clinical management of LGG. Potential new imaging-based research areas that may emerge 
as a result of a shift towards using molecular markers in LGG management will also be 
discussed. 
 
New Knowledge Influencing the Changing Practice in LGG Management 
Assessment of Tumour Growth 
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Studies investigating the growth rate of LGG have consistently demonstrated that LGG grow 
continuously prior to anaplastic progression, despite often appearing static on subjective 
visual analysis of interval imaging examinations demonstrating that LGG are actually not 
 ‘ƐƚĂďůĞ ?ĂƐŝŶŝƚŝĂůůǇƚŚŽƵŐŚƚ. 
 
The majority of studies use velocity of diametric expansion (VDE) as a measure of growth 
rate.16,31 W37 This is obtained from a series of measurements and calculations: the tumour 
volume is measured using axial images and manual segmentation, the volume (V) is used to 
calculate a mean tumour diameter (MTD, MTD=(2xV)1/3), and finally VDE calculated from 
the linear regression of MTD over time.38 Prior to anaplastic progression LGG have been 
demonstrated to grow linearly at a mean VDE of 4mm/yr.38 Further studies used changes in 
tumour volume. Tumour volumes are measured on fluid attenuation inversion recovery 
(FLAIR) series using semi-automated technique to contour the tumour margin on multiple 
axial images with manual editing as required to increase accuracy (see figure 1).4,6 These 
studies found similar results to those measuring VDE: Rees et al. found in a study of 27 
patients that stable LGG grow at a mean annualised percentage growth rate of 16%;4 while 
Caseiras et al. demonstrated in 34 patients with LGG a mean growth over 6 months of 
8.8ml6 (approximately a 24% increase in volume per year). 
 
Figure 1 here 
 
Tumour growth rate is a prognostic indicator of tumour grade, risk of anaplastic progression 
and overall survival.4,6,16,32,38 W41 A VDE greater than 3mm/year correlated with an increased 
risk of anaplastic progression.16 Overall survival of patients was significantly longer in 
patients with a VDE of less than 8mm/year compared with those with a growth rate of 
greater than 8mm/year, as well as increased progression free survival in the slower growth 
rate group.39 There is often an acceleration in growth rate in the six months preceding 
anaplastic progression prior to any clinical deterioration or other imaging features 
suggestive of progression.4,6 Similarly tumour volume at presentation has been 
demonstrated as an independent predictor of time to anaplastic progression.4,6  
 
Despite growth rate and presentation tumour volume being reliable predictors of anaplastic 
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progression and survival based on the handful of studies currently available, there is 
considerable overlap in the tumour volume and growth rates of LGG that remain stable for a 
long period and those that progress rapidly32, suggesting there are other factors important 
for the prediction of progression risk and prognosis. 
 
Molecular Markers 
The emerging understanding of glioma oncogenetics has started to explain the prognostic 
inaccuracies of radiological and clinical biomarkers and the 2007 WHO Classification, whilst 
providing novel, more accurate, molecular biomarkers. 
 
Several molecular markers have been identified in diffuse gliomas (grades II-IV) with 
promising diagnostic and prognostic properties for stratification that could help guide 
clinical decision making, as well as potential predictive properties which may influence 
treatment options. Genome-wide analyses have identified isocitrate dehydrogenase (IDH) 
mutations, 1p19q co-deletion and genetic alterations in tumour protein 53 (TP53), 
telomerase reverse transcriptase (TERT) promoter and alpha thalassaemia/mental 
retardation syndrome X-linked (ATRX) as potential key markers.42 
 
IDH mutations were first discovered in 2008, initially in glioblastoma (GBM)43 and are 
heterozygous somatic point mutations in genes that encode for enzymes involved in the 
Krebs cycle.44 IDH1 mutations are more common than IDH2.44 IDH mutations (1 or 2) occur 
in 65-80% of grade II-III gliomas and secondary GBM (occurring as a result of progression of 
grade II/III tumours), whereas they are uncommon in primary GBM (occurring in 
approximately 5%).44 It has been reported that 75% of astrocytomas, 80% of 
oligodendrogliomas and 80% of oligoastrocytomas display IDH1 mutations.45 It is believed 
that IDH mutations are consistent molecular events which occur early during tumour 
pathogenesis and can therefore often be associated with other mutations,44 most 
commonly TP53 and ATRX in astrocytomas and 1p/19q in oligodendrogliomas.46 W48 
 
Gliomas with IDH mutations tend to occur in younger patients, have a predilection for the 
frontal lobes, are larger at diagnosis, are often non-enhancing and have prevalent cystic and 
diffuse components.42,49,50 Despite being larger at presentation, IDH mutations in gliomas 
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are strong independent predictors of improved overall prognosis. Several studies have 
demonstrated an improved median overall survival for IDH-mutated gliomas, compared 
with patients with IDH-wildtype tumours (i.e. without IDH 1 or 2 mutations).51 W55 The 
median overall survival for IDH-mutated tumours is reported as approximately 8-8.4 years, 
compared with 1.4-1.7 years in IDH-wildtype tumours.42,52 An improved progression free 
survival has also been shown.54,55Grade II and III IDH-wildtype gliomas have a comparable 
survival to primary glioblastomas and have been suggested to therefore behave 
similarly.42,44,47,53 Interestingly, IDH status has no significant effect on the spontaneous 
growth rate of LGG, despite the tumours often being larger at presentation.35,55 
 
It is not yet clear whether IDH status can predict sensitivity to chemotherapy or 
radiotherapy. A recent phase III trial of radiotherapy versus chemotherapy showed a longer 
time to treatment failure associated with IDH mutations but IDH status was not predictive of 
chemotherapy responsiveness.51 IDH mutation may also prove to be a predictive marker in 
aggressive surgical management, with additional survival benefit demonstrated with IDH  W
mutated tumours when surgical resection is extended beyond the enhancing tumour 
margins, however this has only been shown in high-grade gliomas.56 
 
IDH-mutated tumours have been shown to accumulate 2-hydroxyglutarate (2HG) and this 
can be detected non-invasively using magnetic resonance spectroscopy (MRS).57 
Concentrations of 2HG have been demonstrated to vary with tumour activity and increase 
with anaplastic progression, suggesting that 2HG measured by MRS could prove to be an 
accurate non-invasive biomarker in IDH-mutated gliomas.58 However, Chen et al. (2015) 
found in their analysis of 2HG-MRS in 21 patients (blinded to IDH-status) that there was a 
significant false negative rate, most notably in two cases that were negative for 2-HG 
despite progressive disease on conventional MRI.59 This suggests that 2HG cannot currently 
replace tissue diagnosis for determining IDH-status; however further research is needed in 
this area. 
 
On the other hand, 1p/19q codeletion has been recognised for some time as being 
associated with oligodendroglial elements60 and can be seen in both pure and mixed 
oligodendrogliomas.44 There is combined loss of genetic material from the short arm of 
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chromosome 1 and the long arm of chromosome 19, leading to an unbalanced translocation 
and loss of heterozygosity.48 1p/19q codeletion only occurs in the presence of concomitant 
IDH mutations44 and is reported to occur in approximately 80% of oligodendrogliomas.61  
 
The presence of 1p/19q codeletion can aid risk stratification in IDH-mutant gliomas and is 
associated with a significantly longer overall survival. Sabha et al. found that overall survival 
was 97% at 3 years in tumours with codeletion compared with 89.9% in non-codeleted 
tumours.54 Similarly it has been found that having a LGG with a combined 1p/19q codeletion 
and IDH mutation corresponds with a median overall survival of greater than eight years.47 
 
1p/19q codeletion is also associated with an improved response to chemotherapy and 
chemo-radiotherapy as demonstrated in three randomised controlled trials,51,52,62 however 
the mechanism for this is still currently unknown. Furthermore, it has been demonstrated 
that 1p/19q codeletion correlated with a slower growth rate in LGG.33,35 Isolated loss of 1p 
or 19q can also be seen, mainly in astrocytomas, but is not associated with the same degree 
of prognostic benefits as codeletion.48 
 
Other molecular markers which are associated with diffuse gliomas includes TP53, ATRX and 
TERT, however these are less well established. TP53 mutation occurs in 50-60% of 
astrocytomas46,63 and often follows IDH-mutation.42,48,63,64 It also occurs in 
oligodendrogliomas, but is comparatively rare, occurring in 5%.63,65 It is not yet completely 
clear whether TP53 is a reliable prognostic predictor, either independently or in 
combination with other markers. 
 
ATRX is also associated with astrocytic tumours.46,47 It is rare for ATRX mutations to occur 
without concurrent IDH mutations and can be found in 36% of diffuse gliomas46 and 86% of 
IDH-mutated tumours.42 ATRX mutated tumours may represent a subgroup of IDH-mutant 
astrocytomas with a better prognosis as it has been demonstrated that they have a longer 
median time to treatment failure compared with those without the mutation.66 However 
the impact of ATRX mutation on survival and treatment response needs further 
investigation. 
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Mutation in TERT promoter tends to co-occur with 1p/19q codeletion and is therefore 
closely associated with oligodendrogliomas.42,44,67,68 The Cancer Genome Atlas Research 
Network study found that 96% of diffuse gliomas with IDH mutation and 1p/19q codeletion 
also showed TERT promoter mutations, compared with only 4% in tumours with IDH 
mutation but no 1p/19q codeletion.42 Due to the close links between TERT promoter 
mutation and other molecular markers it is unclear what elements of prognostic benefit are 
attributable to TERT status alone. 
 
Figure 2 here 
 
Implications for Neuropathological Classification and Diagnosis 
The new (2016) classification now incorporates molecular genetics and histopathological 
findings into an integrated diagnosis.2,30 The 4-point WHO grading scheme essentially 
remains unchanged, and the first step remains determination of the morphological subtype. 
LGG can be divided into IDH mutant or wild type tumours. Those with ATRX mutation but 
without 1p19q co-deletion are in general astrocytic, whilst oligodendrogliomas are ATRX 
wildtype with 1p19q co-deletion. For the integrated diagnosis, the molecular findings take 
precedence over the morphological appearances in determining whether the tumour should 
be considered oligodendroglioma or astrocytoma in the final report. The implication of this 
is that tumours are defined by the molecular genetics as well as the histological features, 
and that molecular typing allows finer sub-classification of tumour types. Where molecular 
typing cannot be fully assessed, the term NOS (not otherwise specified) is used. The 
oligoastrocytoma remains in the classification as a morphological subtype, but with 
application of molecular subtyping these would be resolved into either astrocytoma or 
oligodendroglioma in the integrated diagnosis. GBM is now classified into Glioblastoma IDH 
mutant or Glioblastoma IDH wildtype (a number of morphological subtypes also remain in 
the classification). 
 
Emerging surgical practice 
Another emergent finding, particularly over the past decade, is that of the benefit of surgical 
resection of LGG, which further refutes the use of expectant management policies. 
Previously it has been argued ƚŚĂƚŝŶ ‘ƐƚĂďůĞ ?>''ǁŝƚŚǁĞůů-controlled symptoms, 
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neurosurgery may cause greater morbidity than benefit due to the risk of secondary long-
term neurological deficits.4 In 2010, Soffietti et al. concluded the evidence for the timing of 
and extent of surgery in LGG to be inconclusive with no randomised trials in this field.63 
However, despite no prospective randomised trials in this area existing, multiple 
prospective observational/cohort and retrospective studies over recent years have 
repeatedly demonstrated increased survival and a reduced risk of anaplastic progression 
with early aggressive resection of LGG compared with biopsy alone/watch and wait 
programmes. 
 
Jakola et al., in their retrospective cohort study of patients with LGG undergoing early 
resection versus biopsy and then watchful waiting in two different centres, demonstrated 
that patients treated with early surgical resection have a better overall survival.69 The 
median overall survival in the biopsy and watchful waiting group was 5.9 years compared 
with an unreached median survival in the early resection group.69 The French Glioma 
Network also concluded from their mixed retrospective and prospective study of 1097 LGG 
that resection gives superior survival compared with stereotactic biopsy, and attribute this 
to a delay in anaplastic progression.70 
 
Several studies have also demonstrated improved survival with increasing extent of 
resection.71 W76 Gross total resection or resection of greater than 90% of the tumour volume 
can produce overall 5 years survival rates of 93-97%, compared with 41-84% for less 
extensive resections or biopsy.72,73,75,76 The risk of recurrence and anaplastic progression 
have also been shown by some to improve with aggressive resective treatment.71,73 This 
improvement in survival with extensive resection is also the case for repeat surgery 
following tumour recurrence.74 ,ŽǁĞǀĞƌƚŚŝƐŚĂƐŶ ?ƚďĞĞŶĐŽŶƐŝƐƚĞŶƚůǇĚĞŵŽŶƐƚƌĂƚĞĚ, with 
other groups showing no significant differences in progression free survival with gross 
tumour resection versus subtotal resection/biopsy.74,76 Seizure control is also reported to be 
improved by total resection, with more than 90% of patients becoming seizure free or 
having a significant improvement in seizures following surgery for LGG.77  
 
Following the demonstration that tumour cells can extend beyond the visible T2/FLAIR 
abnormality on MRI by up to 20mm37 and the above findings on the benefit of aggressive 
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extent of resection, some have gone on further to suggest that, where posƐŝďůĞ ? ‘ƐƵƉƌĂ-ƚŽƚĂů ?
resections (resecting beyond the MRI visible tumour margin) should be attempted and may 
also reduce the risk of anaplastic progression.78,79  
 
Maximising survival chances by attempting the greatest extent of resection possible is 
obviously important, but only if balanced with no significant detrimental effect on the 
quality of life following aggressive surgery, after all the risk of long term deficit was the 
initial rationale for surveillance of stable LGG. The European Federation of Neurological 
Societies (EFNS) and European Association for Neuro-Oncology (EANO) recommend that 
 ‘ƐƵƌŐŝĐĂůƌĞƐĞĐƚŝŽŶŝƐƚŚĞĨŝƌƐƚƚƌĞĂƚŵĞŶƚŽƉƚŝon, with the goal to maximally resect the 
tumour mass whenever possible, whilst minimising post-ŽƉĞƌĂƚŝǀĞŵŽƌďŝĚŝƚǇ ? ?63 The safest 
way to achieve this is by performing an awake craniotomy with intra-operative electrical 
stimulation, resecting according to functional boundaries. This is especially important as 
LGG are frequently located in eloquent areas of brain. In one study intra-operative 
functional brain mapping has been shown to reduce severe permanent neurological deficits 
from 17% to 6.5%, 80 however a recent large scale meta-analysis of 8091 patients from 90 
studies reported permanent deficits in even fewer cases (3.4%).81 The extent of resection is 
also improved with intra-operative mapping, as well as the ability to safely operate within 
eloquent areas.80,81 It has also been shown in a retrospective study of 190 patients that 
adding pre-operative functional MRI (fMRI) or fibre tracking diffusion tensor imaging (DTI) 
to an intra-operative neuro-navigational system can further increase extent of resection.75 
 
This highlights the role of imaging both pre- and post-operatively. With a drive to maximal 
resection as the optimal initial management of LGG, whilst still maintaining a low rate of 
long-term neurological sequelae, pre-operative imaging that clearly identifies anatomic 
structures and tumour boundaries and gives information on functional activity is 
increasingly important in aiding surgical planning. This can be achieved with a variety of 
modalities, including fMRI, PET and DTI.82 However current imaging modalities available are 
not yet as reliable as intra-operative mapping, which is likely to remain the gold standard for 
the time being.83 DTI when compared with intraoperative subcortical language mapping was 
concordant in 81% of cases but negative tractography did not rule out the presence of white 
matter tracks in this area, particularly when invaded by tumour cells.84  
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Due to the infiltrative nature of LGG and the potential for microscopic invasion beyond the 
visible tumour boundary37, it is very unlikely that LGG will be completely resected. Post-
operative imaging is therefore also important. Studies have shown that it is very difficult to 
accurately predict the extent of resection intra-operatively,70,76 which introduces a role for 
intra-operative MRI as this has been shown to improve the extent of resection in gliomas 
when compared with conventional neurosurgery.85 Initial post-operative imaging should be 
performed as early as possible to get an accurate baseline, before post-operative 
inflammation occurs. Haemostatic material used intra-operatively can also cause reactive 
enhancement, restricted diffusion and inflammatory responses.86 Regular longer term post-
operative imaging is also important for follow-up, monitoring for tumour recurrence and 
response to adjuvant chemotherapy or radiotherapy in subtotal tumour resections or where 
genetic make-up indicates the need for adjuvant treatment. 
 
The Changing Role of the Radiologist 
As a result of the above findings, the role of the radiologist in imaging LGG is expected to 
change. Instead of imaging formŝŶŐƚŚĞŵĂŝŶƐƚĂǇĨŽƌŵŽŶŝƚŽƌŝŶŐŽĨƉĂƚŝĞŶƚƐǁŝƚŚ ‘ƐƚĂďůĞ ?
LGG for signs of anaplastic progression, patients are likely to undergo early aggressive 
surgical resection without prior biopsy to confirm the nature of the tumour. Genetic 
markers have radically changed the categorisation of diffuse gliomas as is reflected in the 
updated 2016 WHO Classification.2 MRI will therefore play a key role in the identification of 
LGG and distinguishing it from other non-neoplastic lesions, especially when the 
abnormality is small. Advanced MRI biomarkers may be developed and in the future provide 
reliable non-invasive methods for accurately determining genetic and molecular make-up of 
gliomas. Exploration is needed into the optimum management for indeterminate lesions, 
the ideal timing for interval imaging and the potential risks in delaying treatment if the 
lesion is later confirmed to be a LGG.  
 
Accurate pre-operative imaging will be required to enable safe surgical planning. However, 
inter-individual variations have been shown to exist in anatomic location of various brain 
functions,65 as well as a suboptimal concordance between DTI and intraoperative language 
mapping.84 The role and accuracy of advanced imaging techniques such as DTI tractography 
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and functional MRI in defining tumour boundaries and infiltration into functional brain 
tissue needs exploring further, but should be available to supplement conventional 
anatomic imaging in surgical planning where believed to be beneficial in reducing the risk of 
long-term neurological deficit. This will complement the existing intra-operative brain 
mapping along with possibly introducing intra-operative MRI where facilities exist. 
Accurately defining the tumour boundary is also important to enable maximal resection. 
Arbizu et al. suggest there may be role for metabolic imaging using 11C-methionine positron 
emission tomography (PET) for distinguishing the margins of LGG from perilesional 
oedema.87 
 
Improved knowledge into pathways of tumour cell migration and infiltration along white 
matter tracts is also important and how this effects appearances on DTI. Following early 
resection and the consequent improved overall survival there will be prolonged follow-up of 
patients and so identifying subtle and new areas of tumour recurrence or progression will 
become the predominant role of the radiologist. Investigation into the optimum timing and 
intervals for follow-up is needed and whether this should be modified according to the 
tumour genetics.  
 
Depending on tumour genetics, patients may undergo chemotherapy and/or radiotherapy 
as well as surgery. This will bring further challenges in the interpretation of post-treatment 
imaging and the identification of recurrence/progression versus pseudo-progression but this 
is outside the scope of this article. 
 
Overall the role of the radiologist will change from one of monitoring for anaplastic 
progression to accurate early identification of LGG, delineation of tumour boundaries and 
facilitating safe aggressive surgical resection along with post-treatment follow-up imaging 
for tumour recurrence. 
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Figure 1 
 
 
 
 
 
Figure 1: Axial FLAIR image with Gadolinium showing contour around the tumour margin 
used to calculate tumour volume. The overall tumour volume is the product of the 
contoured areas on each axial slice, the slice thickness and inter-slice gap. 
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Figure 2. 
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